Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which vein is safer for chemotherapy ports? a trial aims to settle the debate

NCT ID NCT03945045

Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial compares two common methods for placing a totally implantable vascular access device (TIVAD), a port used for chemotherapy and other treatments in cancer patients. Researchers are randomly assigning patients to have the port inserted via either the internal jugular vein (neck) or the subclavian vein (chest). The goal is to see which approach leads to fewer complications, such as blood clots, infections, or device malfunctions, over two years of follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a procedure comparing two vein approaches (internal jugular vein vs. subclavian vein) for implanting a totally implantable vascular access device (TIVAD)
What this could lead to
If one approach proves safer, it could become the standard method for placing long-term central lines in cancer patients, reducing complications like blood clots and infections.
What could go wrong
This is a single-center trial with 240 patients, so results may not apply to all settings. The study focuses on short-term complications and does not address long-term device performance beyond two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

201 people

The number who actually took part.

Started

May 2019

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: 240 cancer patients, 20\~99 years old. Exclusion: 1. Breast cancer, mediastinal tumor above 6 cm, head and neck cancer with/without surgical/radiological treatment, lung tumor above 6 cm, 2. ECOG (Eastern Cooperative Oncology Group)performance status\>=2, can't tolerate sit-upright or standing postoperative chest plain film, 3. Allergy to prophylactic antibiotic, 4. History of previous TIVAD or Hickman catheter implantation. Recent 2 weeks Central venous catheter insertion. 5. End stage renal disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Catheter-Related Infections thrombophilia due to thrombin defect Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Catheter mechanical failure rate Catheter-related infections Venous thrombosis

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.